FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2226131330> ?p ?o ?g. }

• W2226131330 endingPage "4705" @default.
• W2226131330 startingPage "4705" @default.
• W2226131330 abstract "4705 Background: Taxane (T) based chemotherapy improves survival in patients (pts) with progressive CMPC. A high frequency of non-cancer related factors places this group at risk for toxicities which can result in dose reductions and treatment delays that may compromise overall outcomes. We explored associations between age, baseline characteristics and co-morbidities and the ability to administer chemotherapy in CMPC. Methods: We evaluated the delivered chemotherapy to 108 sequentially treated men enrolled on clinical trials for progressive CMPC treated with T or Epothilone (E) based regimens. Multi-variate analysis was performed to determine the predictors of dose reduction, delay or discontinuation of therapy due to toxicity. Studied were: age, Charlson Co-Morbidity, stage at diagnosis, Gleason grade, Karnofsky performance status (KPS), extent of disease, and baseline biochemical parameters. Results: The median age was 68 (range 52–84), KPS: 90 (range 70–90); PSA 95 ng/ml (range .5–1923 ng/ml), HGB 12.7 g/dl (range 8.2–15.7g/dl), Gleason 8 (range 4–10) Tumor 3 (range 1–4) of whom 66 (61%) received a T, 42 (39%) E, and 19% had significant co-morbidities (cardiovascular, diabetes or gastrointestinal). For the overall group dose reductions were seen in 52%, delays in 56%, and 44% discontinued therapy prematurely after a median of 5 (range 1 to 16) cycles. Most common reason to delay or reduce chemotherapy was leukopenia in 31%, and neurotoxicity in 19%. Significant associations existed with dose reduction (P<0.0001), delay (P=0.0039) or discontinuation (P=0.0082) depending on either T or E administered. Initial M stage (P=0.03) and age (0.09) trended to predict for discontinuing therapy. There was no association between co-morbidities and other baseline parameters to predict dose reduction, delay or discontinuation of chemotherapy. Conclusions: Toxicities requiring dose modifications occur frequently in pts with progressive CMPC treated with T based chemotherapy. The toxicities were regimen specific, and did not appear to be related to co-morbidities in a patient group that met the eligibility criteria for Phase II clinical trials. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis" @default.
• W2226131330 created "2016-06-24" @default.
• W2226131330 creator A5031035765 @default.
• W2226131330 creator A5048752643 @default.
• W2226131330 creator A5050512386 @default.
• W2226131330 creator A5063435994 @default.
• W2226131330 creator A5072850546 @default.
• W2226131330 creator A5081246052 @default.
• W2226131330 creator A5087366631 @default.
• W2226131330 date "2005-06-01" @default.
• W2226131330 modified "2023-10-16" @default.
• W2226131330 title "Association of age, baseline characteristics, co-morbidity and toxicity in castrate metastatic prostate cancer patients (CMPC) treated with chemotherapy" @default.
• W2226131330 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4705" @default.
• W2226131330 hasPublicationYear "2005" @default.
• W2226131330 type Work @default.
• W2226131330 sameAs 2226131330 @default.
• W2226131330 citedByCount "0" @default.
• W2226131330 crossrefType "journal-article" @default.
• W2226131330 hasAuthorship W2226131330A5031035765 @default.
• W2226131330 hasAuthorship W2226131330A5048752643 @default.
• W2226131330 hasAuthorship W2226131330A5050512386 @default.
• W2226131330 hasAuthorship W2226131330A5063435994 @default.
• W2226131330 hasAuthorship W2226131330A5072850546 @default.
• W2226131330 hasAuthorship W2226131330A5081246052 @default.
• W2226131330 hasAuthorship W2226131330A5087366631 @default.
• W2226131330 hasConcept C121608353 @default.
• W2226131330 hasConcept C126322002 @default.
• W2226131330 hasConcept C126894567 @default.
• W2226131330 hasConcept C141071460 @default.
• W2226131330 hasConcept C143998085 @default.
• W2226131330 hasConcept C2776694085 @default.
• W2226131330 hasConcept C2780192828 @default.
• W2226131330 hasConcept C29730261 @default.
• W2226131330 hasConcept C71924100 @default.
• W2226131330 hasConceptScore W2226131330C121608353 @default.
• W2226131330 hasConceptScore W2226131330C126322002 @default.
• W2226131330 hasConceptScore W2226131330C126894567 @default.
• W2226131330 hasConceptScore W2226131330C141071460 @default.
• W2226131330 hasConceptScore W2226131330C143998085 @default.
• W2226131330 hasConceptScore W2226131330C2776694085 @default.
• W2226131330 hasConceptScore W2226131330C2780192828 @default.
• W2226131330 hasConceptScore W2226131330C29730261 @default.
• W2226131330 hasConceptScore W2226131330C71924100 @default.
• W2226131330 hasIssue "16_suppl" @default.
• W2226131330 hasLocation W22261313301 @default.
• W2226131330 hasOpenAccess W2226131330 @default.
• W2226131330 hasPrimaryLocation W22261313301 @default.
• W2226131330 hasRelatedWork W1990875800 @default.
• W2226131330 hasRelatedWork W2046284161 @default.
• W2226131330 hasRelatedWork W2056760970 @default.
• W2226131330 hasRelatedWork W2094570582 @default.
• W2226131330 hasRelatedWork W2154524007 @default.
• W2226131330 hasRelatedWork W2183543225 @default.
• W2226131330 hasRelatedWork W2263206436 @default.
• W2226131330 hasRelatedWork W2299690226 @default.
• W2226131330 hasRelatedWork W2735900144 @default.
• W2226131330 hasRelatedWork W2776356588 @default.
• W2226131330 hasVolume "23" @default.
• W2226131330 isParatext "false" @default.
• W2226131330 isRetracted "false" @default.
• W2226131330 magId "2226131330" @default.
• W2226131330 workType "article" @default.